Endonovo Therapeutics Inc. (ENDV) Appoints Strateg
Post# of 416
(Total Views: 968)
Posted On: 10/21/2019 4:04:18 PM
Endonovo Therapeutics Inc. (ENDV) Appoints Strategic Advisor to the CEO to Explore Growth Opportunities
- The new strategic advisor, Dr. William Li, is a globally recognized medical professional
- One of Li’s primary specialties is the identification of unmet medical market needs that can be addressed through technological advances
- Endonovo is working to develop solutions for major therapeutic needs, especially in regard to pain management
- Its Electroceutical® SofPulse® is clinically proven to provide post-operative pain relief and speed up recovery
On September 30, 2019, Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of innovative medical devices, announced the appointment of Dr. William Li as a strategic advisor to the CEO. The role of Li would be to strategically explore growth opportunities within the Endonovo target markets, the company said in a press release (http://nnw.fm/z5T9v).
“Dr. Li is a globally recognized medical professional and a business visionary with a strong track record of success,” Endonovo Therapeutics CEO Alan Collier said in a news release. Just like the Endonovo team, Li sees the long-term potential of medical innovations and their ability to change the industry, Collier added.
According to Li, “Endonovo has a strong technology platform with game changing potential. The company’s clinical-stage wearable Electroceutical® therapeutic device, SofPulse®, can address pain, wound healing, post-surgical pain, edema, central nervous system disorders and various other conditions.”
“Endonovo is poised to go to the next level across a range of industry verticals. I look forward to working with Alan and the Endonovo team to evaluate the Company’s operational and strategic opportunities,” Li added.
One of Li’s focal areas of experience is the identification of unmet needs in the healthcare space, especially if cost-effective innovative technology can offer a solution.
Li is the CEO and co-founder of the Angiogenesis Foundation. He gained experience under the guidance of Dr. Judah Folkman – one of the angiogenesis pioneers. Li has been actively involved in angiogenesis and clinical research for more than 30 years. Li graduated from Harvard and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as a consultant to various leading global public and private companies.
Endonovo Therapeutics is currently developing solutions to meet major therapeutic needs. The company’s innovative SofPulse® device delivers clinically proven post-operative pain relief for patients, reducing the need for opioid use.
SofPulse® delivers targeted pulsed electromagnetic field therapy to significantly speed up the recovery process after surgery. It improves the patient’s natural recovery experience and can be a better alternative to opioid-based pain medications, thus helping tackle the current opioid crisis.
According to U.S. federal statistics, opioids kill more people per year than automobile accidents. In 2018 alone, 68,000 Americans died of a drug overdose stemming from opioid abuse (http://nnw.fm/gT4Wv). This is a significant increase from 18,515 opioid-related deaths in 2007.
The general population and the medical community are both pushing for a change in which chronic and post-operative pain are handled. Unfortunately, few alternatives to opioids exist. SofPulse® is one of the innovative solutions that could diminish the use of medications and give patients satisfactory pain management.
Endonovo’s therapy is cleared by the U.S. Food and Drug Administration for the palliative treatment of post-surgical pain and edema. It is also CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The new strategic advisor, Dr. William Li, is a globally recognized medical professional
- One of Li’s primary specialties is the identification of unmet medical market needs that can be addressed through technological advances
- Endonovo is working to develop solutions for major therapeutic needs, especially in regard to pain management
- Its Electroceutical® SofPulse® is clinically proven to provide post-operative pain relief and speed up recovery
On September 30, 2019, Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of innovative medical devices, announced the appointment of Dr. William Li as a strategic advisor to the CEO. The role of Li would be to strategically explore growth opportunities within the Endonovo target markets, the company said in a press release (http://nnw.fm/z5T9v).
“Dr. Li is a globally recognized medical professional and a business visionary with a strong track record of success,” Endonovo Therapeutics CEO Alan Collier said in a news release. Just like the Endonovo team, Li sees the long-term potential of medical innovations and their ability to change the industry, Collier added.
According to Li, “Endonovo has a strong technology platform with game changing potential. The company’s clinical-stage wearable Electroceutical® therapeutic device, SofPulse®, can address pain, wound healing, post-surgical pain, edema, central nervous system disorders and various other conditions.”
“Endonovo is poised to go to the next level across a range of industry verticals. I look forward to working with Alan and the Endonovo team to evaluate the Company’s operational and strategic opportunities,” Li added.
One of Li’s focal areas of experience is the identification of unmet needs in the healthcare space, especially if cost-effective innovative technology can offer a solution.
Li is the CEO and co-founder of the Angiogenesis Foundation. He gained experience under the guidance of Dr. Judah Folkman – one of the angiogenesis pioneers. Li has been actively involved in angiogenesis and clinical research for more than 30 years. Li graduated from Harvard and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as a consultant to various leading global public and private companies.
Endonovo Therapeutics is currently developing solutions to meet major therapeutic needs. The company’s innovative SofPulse® device delivers clinically proven post-operative pain relief for patients, reducing the need for opioid use.
SofPulse® delivers targeted pulsed electromagnetic field therapy to significantly speed up the recovery process after surgery. It improves the patient’s natural recovery experience and can be a better alternative to opioid-based pain medications, thus helping tackle the current opioid crisis.
According to U.S. federal statistics, opioids kill more people per year than automobile accidents. In 2018 alone, 68,000 Americans died of a drug overdose stemming from opioid abuse (http://nnw.fm/gT4Wv). This is a significant increase from 18,515 opioid-related deaths in 2007.
The general population and the medical community are both pushing for a change in which chronic and post-operative pain are handled. Unfortunately, few alternatives to opioids exist. SofPulse® is one of the innovative solutions that could diminish the use of medications and give patients satisfactory pain management.
Endonovo’s therapy is cleared by the U.S. Food and Drug Administration for the palliative treatment of post-surgical pain and edema. It is also CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼